-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $20

Benzinga·05/02/2025 12:39:18
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $20.